The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
It is developing the drug candidate to potentially treat immunological diseases
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
In clinical trials, treatment proved more effective than other therapies evaluated
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
The plan is to advance innovative therapies to drug-resistant cancers
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Subscribe To Our Newsletter & Stay Updated
